Galderma has received European Union approval for Restylane Shaype, a hyaluronic acid injectable developed for chin augmentation.
Restylane Shaype is marketed as the first bone-mimicking hyaluronic acid product intended for facial shaping within the European market. The treatment utilizes specialized technology designed to mimic the structural properties of bone to achieve precise contouring results.
Regulatory clearance in the EU permits Galderma to commercialize the product for chin augmentation procedures across member states. Further details regarding commercial rollout timelines and distribution plans have not yet been disclosed.
